- Home
- Companies
- netherlands
- antigen presentation
Show results for
Refine by
Antigen Presentation Suppliers Serving Netherlands
34 companies found
based inMunich, GERMANY
ImevaX is a Biotech company based in Munich with a focus on facilitating H. pylori Diagnostics with a novel Rapid Diagnostic ...
(cytotoxin-associated antigen A) is one of the best studied and most important virulence factors. Subjects infected with H. pylori strains expressing CagA have a significant higher risk to develop complications, including gastric cancer, compared to ...
based inLublin, POLAND
We are a Polish biotechnology company with long manufacturing traditions. We have been present on the Polish and international markets since 1944. We are challenged and truly honoured to provide the leading, innovative medical solutions, and, due to ...
Name of the Medicinal Product Gamma anty-D 50, 50 micrograms/ml Solution for injection. Qualitative and Quantitative Composition: 1 ml of the solution consists of: Human anti-D immunoglobulin 50 micrograms (250 IU) . Human protein content not less ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
CD1d Tetramers the world’s leading product for tracking NKT cells. Detect NKT Cells with CD1d Tetramers: ProImmune is the leading commercial source worldwide for fluorescently labeled human and mouse CD1d tetramers. CD1d-lipid complexes bind ...
based inChatham, NEW JERSEY (USA)
Tonix is a clinical-stage biopharmaceutical company focused on developing novel therapies and vaccines to prevent and treat central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. At Tonix, we are focused on ...
TNX-1850 is the planned new version of the TNX-1800 vaccine that encodes spike protein from SARS-CoV-2 BA.2 ...
based inLangenfeld, GERMANY
ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production. We develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ...
based inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
based inCarlsbad, CALIFORNIA (USA)
Founded in 1996, IVD Research, Inc. is privately held by Dave Lambillotte, Ann Marie Martin and Christopher Lambillotte. Our tight-knit group of dedicated professionals works well as a team, each bringing their own unique experiences and education ...
Giardiasis, caused by the single-celled Giardia lambliaparasite, is the most common parasitic disease in the United States. As many as 100 million mild infections and 1 million severe infections are reported ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process ...
based inOslo, NORWAY
NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer ...
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in ...
based inLoveland, COLORADO (USA)
Through innovation, invention, and strategic partnerships with worldwide leaders in diagnostics and treatments, Heska provides the benefits of latest generation technologies to pet healthcare providers. Heska’s range of complete blood diagnostic ...
The safest long term allergy treatment solution for canine, feline or equine ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
Our therapies are focused on leveraging the inherent biological capabilities of gamma delta T cells (GDT cells) together with an integrated cell engineering approach. GDT cells are a component of the lymphocytes (white blood cells) present within ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inOxford, UNITED KINGDOM
The Native Antigen Company has developed a proprietary HEK293 mammalian expression system (VirtuE) for expression of recombinant proteins. The Native Antigen Company has rapidly become one of the world’s leading suppliers of infectious disease ...
Recombinant Chikungunya Virus-Like Particles produced in mammalian HEK293 cells. Chikungunya structural proteins are transiently expressed to form a particle comprising E1, E2 and capsid protein, without the non-structural proteins or genome. ...
based inNew Taipei City, TAIWAN
For EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their ...
CRM197 has been tested in animals studies and it has been demonstrated to lack toxicity. CRM197 can be used as a carrier protein for vaccine delivery. It acts by helping polysaccharide antigens to bind on and be internalized into ...
based inWayne, PENNSYLVANIA (USA)
Sino Biological is committed to providing high-quality recombinant protein and antibody reagents and to being a one-stop technical services shop for life science researchers around the world. All of our products are independently developed and ...
FCAR, also called FcαRI or CD89, is a type I transmembrane receptor for Fc region of IgA which is the most abundant immunoglobulin in mucosal areas but is only the second most common antibody isotype in serum. This receptor is present on the ...
based inSeocho-gu, NORTH KOREA
We, JW Holdings, are moving forward toward global healthcare group. JW Holdings, as a holding company, we are concentrating all our efforts to ensure stable growth of business companies including JW Pharmaceutical, JW Shinyak, JW Life Science, JW ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Vγ9Vδ2 T cells belong to the first line of defense against cancer and have the potential to elicit deep and durable responses in the ...
based inBelfast, UNITED KINGDOM
Biopanda Reagents develops and manufactures in vitro test kits for clinical laboratories, veterinary practice, environmental protection, and food safety, both locally and globally. Our company provides innovative, high quality and cost-effective ...
The Biopanda TB-ELiFN kit is an enzyme linked immunosorbent assay (ELISA) for the quantitative determination of Interferon gamma (IFN-γ) released by memory T cells in human whole blood through in vitro stimulation with specific Mycobaterium ...
based inCambridge, MASSACHUSETTS (USA)
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP ...
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, ...